NYSE:BHVNBiotechs
Biohaven (BHVN) Is Up 19.2% After Early Success With Selective Antibody Degraders In Kidney, Thyroid Diseases
Biohaven recently reported positive early clinical experience with its first-in-class extracellular protein degraders in IgA nephropathy and Graves' disease, showing rapid removal of disease-causing proteins and associated clinical improvements, and secured FDA alignment on a pivotal IgA nephropathy study planned to start in early 2026.
A distinctive aspect of this update is Biohaven's ability to selectively target pathogenic antibodies while sparing healthy ones, highlighting the potential...